The AcCREDiT 2 Study

Launched by MANCHESTER UNIVERSITY NHS FOUNDATION TRUST · Jun 11, 2025

Keywords

ClinConnect Summary

The AcCREDiT 2 study is looking at people who come to the hospital with breathing problems caused by lung infections, like pneumonia, or flare-ups of long-term lung conditions such as chronic obstructive pulmonary disease (COPD). These problems can be caused by germs like bacteria, viruses, or fungi, but sometimes doctors can’t find the exact cause. The study aims to see how well new, faster tests can identify the cause of these lung problems compared to traditional lab tests, which usually take several days. This is important because getting the right treatment quickly can help patients recover faster and avoid unnecessary medicines like antibiotics, which can have side effects and lose their effectiveness if overused.

People who are 18 or older, have a suspected lung infection or flare-up, and are about to receive treatment with antibiotics, antiviral, antifungal, or anti-inflammatory medicines may be eligible to take part. Participants will be asked to provide samples like spit, blood, or stool before starting treatment, but the study will not change any care or give experimental treatments. Instead, it will observe and collect information to help improve future tests. The study also focuses on making the consent process easier, especially for very sick patients, by allowing verbal or delayed consent. This is a smaller “feasibility” study to make sure the approach works well before a bigger study is done.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Clinically suspected acute respiratory infection or exacerbation of chronic respiratory disease
• • Availability of respiratory tract sample
• • 1. Spontaneously breathing patients are able to produce a sputum sample
• • 2. Mechanically ventilated patients in intensive care are due to have an Bronchoalveolar lavage or non-directed bronchial lavage for a clinical indication
• * Due to receive either:
• • 1. an anti-infective agent (e.g. antibiotic, antiviral or antifungal) OR
• • 2. a systemic anti-inflammatory agent (e.g. corticosteroid)
• • Valid informed consent, assent or enrolment through deferred consent
• • Re-enrolment will be allowed if presenting for a separate acute event
• Exclusion Criteria:
• • Alternate respiratory cause of presentation in the opinion of the treating physician (e.g. pulmonary embolism, heart failure, etc.)
• • High clinical likelihood of infection with a Hazard Group 3 pathogen (e.g. tuberculosis, anthrax, plague)